220 related articles for article (PubMed ID: 11489843)
41. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
42. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.
Luo Y; Hradil VP; Frost DJ; Rosenberg SH; Gordon GB; Morgan SJ; Gagne GD; Cox BF; Tahir SK; Fox GB
Anticancer Drugs; 2009 Jul; 20(6):483-92. PubMed ID: 19398903
[TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
44. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
45. [The effect of basic fibroblast growth factor in ovarian cancer growth and angiogenesis].
Lin W; Peng ZL; Zheng A; Bi JH; Huang ZY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):532-5. PubMed ID: 14669225
[TBL] [Abstract][Full Text] [Related]
46. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
Brantley DM; Cheng N; Thompson EJ; Lin Q; Brekken RA; Thorpe PE; Muraoka RS; Cerretti DP; Pozzi A; Jackson D; Lin C; Chen J
Oncogene; 2002 Oct; 21(46):7011-26. PubMed ID: 12370823
[TBL] [Abstract][Full Text] [Related]
47. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation.
Cao Y; Li CY; Moeller BJ; Yu D; Zhao Y; Dreher MR; Shan S; Dewhirst MW
Cancer Res; 2005 Jul; 65(13):5498-505. PubMed ID: 15994919
[TBL] [Abstract][Full Text] [Related]
48. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo.
Jia WD; Xu GL; Sun HC; Wang L; Xu RN; Xue Q
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):404-9. PubMed ID: 14599948
[TBL] [Abstract][Full Text] [Related]
49. Recombinant human epidermal growth factor and corneal neovascularization.
Nezu E; Ohashi Y; Kinoshita S; Manabe R
Jpn J Ophthalmol; 1992; 36(4):401-6. PubMed ID: 1289616
[TBL] [Abstract][Full Text] [Related]
50. Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A.
Benelli U; Ross JR; Nardi M; Klintworth GK
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):274-82. PubMed ID: 9040459
[TBL] [Abstract][Full Text] [Related]
51. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules.
Dueñas Z; Torner L; Corbacho AM; Ochoa A; Gutiérrez-Ospina G; López-Barrera F; Barrios FA; Berger P; Martínez de la Escalera G; Clapp C
Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2498-505. PubMed ID: 10509642
[TBL] [Abstract][Full Text] [Related]
53. The effect of total-body irradiation on corneal neovascularization in the Fischer 344 rat after chemical cauterization.
Scroggs MW; Proia AD; Smith CF; Halperin EC; Klintworth GK
Invest Ophthalmol Vis Sci; 1991 Jun; 32(7):2105-11. PubMed ID: 1711517
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
55. A strategy to discover circulating angiogenesis inhibitors generated by human tumors.
Chen C; Parangi S; Tolentino MJ; Folkman J
Cancer Res; 1995 Oct; 55(19):4230-3. PubMed ID: 7545537
[TBL] [Abstract][Full Text] [Related]
56. Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors.
Wagner CR; Ballato G; Akanni AO; McIntee EJ; Larson RS; Chang S; Abul-Hajj YJ
Cancer Res; 1997 Jun; 57(12):2341-5. PubMed ID: 9192804
[TBL] [Abstract][Full Text] [Related]
57. Microcirculatory studies in rat mammary carcinoma. I. Transparent chamber method, development of microvasculature, and pressures in tumor vessels.
Peters W; Teixeira M; Intaglietta M; Gross JF
J Natl Cancer Inst; 1980 Sep; 65(3):631-42. PubMed ID: 6157856
[TBL] [Abstract][Full Text] [Related]
58. Effect of maltose tetrapalmitate on tumor vascularization and tumor growth.
Benrezzak O; Bissonnette E; Madarnas P; Nigam VN
Anticancer Res; 1989; 9(6):1815-8. PubMed ID: 2483306
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995).
Danesi R; Agen C; Benelli U; Paolo AD; Nardini D; Bocci G; Basolo F; Campagni A; Tacca MD
Clin Cancer Res; 1997 Feb; 3(2):265-72. PubMed ID: 9815682
[TBL] [Abstract][Full Text] [Related]
60. In vivo measurement of corneal angiogenesis with video data acquisition and computerized image analysis.
Conrad TJ; Chandler DB; Corless JM; Klintworth GK
Lab Invest; 1994 Mar; 70(3):426-34. PubMed ID: 7511717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
